Pfizer’s Lorlatinib Shows Sustained Efficacy in Lung Cancer Trial, Study Finds
A Phase 3 clinical trial of Pfizer’s drug lorlatinib for non-small cell lung cancer (NSCLC) has confirmed long-term benefits, according to recent updates from the study’s lead researchers. The findings, published in the *New England Journal of Medicine*, highlight the drug’s effectiveness in targeting specific genetic mutations, offering hope for patients with advanced disease.
What Is the CROWN Study and How Does Lorlatinib Work?
The CROWN study, initiated in 2017, evaluated lorlatinib as a treatment for patients with ALK-positive NSCLC. The drug works by inhibiting the ALK protein, which is overactive in certain cancers. Results from the trial, which included over 200 participants, showed that lorlatinib significantly prolonged progression-free survival compared to earlier ALK inhibitors.
What Are the Latest Findings From the Trial?
Seven years after the trial’s start, researchers reported that lorlatinib maintained its efficacy, with continued disease control in patients. “The data demonstrate that lorlatinib remains a robust treatment option, even after long-term follow-up,” said Dr. Sarah M. Johnson, a lead investigator at the National Cancer Institute. The study also noted a lower risk of central nervous system progression, a common challenge in ALK-positive cancers.
How Does Lorlatinib Compare to Other Treatments?
Lorlatinib has been compared to other ALK inhibitors like alectinib and crizotinib. A 2022 analysis in *JAMA Oncology* found that lorlatinib outperformed these drugs in delaying tumor growth, particularly in patients with brain metastases. However, the drug’s side effects, including weight gain and elevated cholesterol, require careful monitoring, as noted by the FDA in its 2021 approval guidelines.
Why Does This Matter for Patients and Doctors?
The sustained efficacy of lorlatinib underscores its role as a first-line treatment for ALK-positive NSCLC. “This is a critical advancement for patients who may have limited options,” said Dr. Michael Chen, an oncologist at Memorial Sloan Kettering Cancer Center. The findings also emphasize the importance of ongoing research into targeted therapies for precision medicine.
What’s Next for Lorlatinib Research?
Pfizer is currently exploring combinations of lorlatinib with other drugs to further improve outcomes. A Phase 2 trial, expected to conclude in 2025, will assess its effectiveness in patients with resistant tumors. Meanwhile, the CROWN study’s long-term data will inform guidelines for ALK inhibitor use in clinical practice.
Key Takeaways
- Lorlatinib shows sustained efficacy in treating ALK-positive lung cancer, with long-term follow-up data supporting its use.
- The drug outperforms earlier ALK inhibitors in delaying disease progression, particularly in brain metastases.
- Side effects like weight gain and cholesterol changes require monitoring, per FDA guidelines.
- Ongoing research aims to optimize lorlatinib’s use in combination therapies and resistant cases.